ORIGINAL PAPER
Gadolinium-ethoxybenzyl-diethylenetriamine (Gd-EOB-DTPA)-
enhanced magnetic resonance imaging with various enhancement
ratios: a correlation with clinical assessment of liver function using
the Child-Pugh scoring system
1
Department of Diagnostic Imaging, Jan Kochanowski University, Kielce, Poland
2
Department of Diagnostic Imaging, Voivodeship Hospital, Kielce, Poland
3
Department of Infectious Diseases, Jan Kochanowski University, Kielce, Poland
4
Department of Clinical Radiology, Medical University of Warsaw, Warsaw, Poland
Submission date: 2021-12-06
Acceptance date: 2021-12-27
Publication date: 2021-12-31
Medical Studies 2021;37(4):279-287
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Liver cirrhosis has been becoming a major cause of mortality in developed countries. Recently, the increasing role of magnetic resonance imaging (MRI) in the diagnosis of liver cirrhosis has been emphasized. For grading of liver fibrosis, various quantitative parameters have been proposed, such as contrast enhancement index (CEI), contrast enhancement ratio (CER), liver-to-muscle ratio (LMR) and liver-to-spleen ratio (LSR). Their role in the assessment of the liver function has not yet been thoroughly investigated.
Aim of the research: To determine whether there is a correlation between hepatocyte-specific contrast-enhanced MRI and liver function impairment classified by the Child-Pugh scoring system in patients with cirrhosis thirty two.
Material and methods:
Ninety four patients with cirrhosis and thirty two patients with clinically healthy liver who underwent gadolinium ethoxybenzyl-diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced MR imaging were enrolled in this study. Patients from the study group were divided into three subgroups according to the Child-Pugh scoring system. The values of all four enhancement ratios (CEI, CER, LMR and LSR) were compared between groups.
Results:
The mean values of all four parameters were significantly lower in patients with moderate or severe liver function impairment (Child-Pugh B and Child-Pugh C) than in patients with mild impairment (Child-Pugh A). Amongst all parameters, CER and LMR showed the best correlation with liver function impairment (r = –0.57 and r = –0.58, respectively).
Conclusions:
Our study showed a good correlation between quantitative evaluation of the liver function using Gd-EOB-DTPA MR imaging and clinical assessment in patients with cirrhosis.
Liver cirrhosis has been becoming a major cause of mortality in developed countries. Recently, the increasing role of magnetic resonance imaging (MRI) in the diagnosis of liver cirrhosis has been emphasized. For grading of liver fibrosis, various quantitative parameters have been proposed, such as contrast enhancement index (CEI), contrast enhancement ratio (CER), liver-to-muscle ratio (LMR) and liver-to-spleen ratio (LSR). Their role in the assessment of the liver function has not yet been thoroughly investigated.
Aim of the research: To determine whether there is a correlation between hepatocyte-specific contrast-enhanced MRI and liver function impairment classified by the Child-Pugh scoring system in patients with cirrhosis thirty two.
Material and methods:
Ninety four patients with cirrhosis and thirty two patients with clinically healthy liver who underwent gadolinium ethoxybenzyl-diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced MR imaging were enrolled in this study. Patients from the study group were divided into three subgroups according to the Child-Pugh scoring system. The values of all four enhancement ratios (CEI, CER, LMR and LSR) were compared between groups.
Results:
The mean values of all four parameters were significantly lower in patients with moderate or severe liver function impairment (Child-Pugh B and Child-Pugh C) than in patients with mild impairment (Child-Pugh A). Amongst all parameters, CER and LMR showed the best correlation with liver function impairment (r = –0.57 and r = –0.58, respectively).
Conclusions:
Our study showed a good correlation between quantitative evaluation of the liver function using Gd-EOB-DTPA MR imaging and clinical assessment in patients with cirrhosis.
REFERENCES (33)
1.
Zhou WC, Zhang QB, Qiao L. Pathogenesis of liver cirrhosis. World J Gastroenterol 2014; 20: 7312-7324.
2.
Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet 2014; 383: 1749-1761.
3.
Pinheiro D, Dias I, Ribeiro Silva K, Stumbo AC, Thole A, Cortez E, de Carvalho L, Weiskirchen R, Carvalho S. Mechanisms underlying cell therapy in liver fibrosis: an overview. Cells 2019; 8: 1339.
4.
Lai M, Afdhal NH. Liver fibrosis determination. Gastroenterol Clin North Am 2019; 48: 281-289.
5.
Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology 2019; 156: 1264-1281.e4.
6.
Sharma S, Khalili K, Nguyen GC. Non-invasive diagnosis of advanced fibrosis and cirrhosis. World J Gastroenterol 2014; 20: 16820-16830.
7.
Lambrecht J, Verhulst S, Mannaerts I, Reynaert H, van Grunsven LA. Prospects in non-invasive assessment of liver fibrosis: liquid biopsy as the future gold standard? Biochim Biophys Acta Mol Basis Dis 2018; 1864: 1024-1036.
8.
Potretzke TA, Saling LJ, Middleton WD, Robinson KA. Bleeding complications after percutaneous liver biopsy: do subcapsular lesions pose a higher risk? AJR Am J Roentgenol 2018; 211: 204-210.
9.
Lurie Y, Webb M, Cytter-Kuint R, Shteingart S, Lederkremer GZ. Non-invasive diagnosis of liver fibrosis and cirrhosis. World J Gastroenterol 2015; 21: 11567-11583.
10.
Sebastiani G, Gkouvatsos K, Pantopoulos K. Chronic hepatitis C and liver fibrosis. World J Gastroenterol 2014; 20: 11033-11053.
11.
Bakan AA, Inci E, Bakan S, Gokturk S, Cimilli T. Utility of diffusion-weighted imaging in the evaluation of liver fibrosis. Eur Radiol 2012; 22: 682-687.
12.
Nishie A, Asayama Y, Ishigami K, Tajima T, Kakihara D, Nakayama T, Takayama Y, Okamoto D, Taketomi A, Shirabe K, Fujita N, Obara M, Yoshimitsu K, Honda H. MR prediction of liver fibrosis using a liver-specific contrast agent: superparamagnetic iron oxide versus Gd-EOB-DTPA. J Magn Reson Imaging 2012; 36: 664-671.
13.
Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology 2017; 66: 1486-1501.
14.
Lewin M, Poujol-Robert A, Boëlle PY, Wendum D, Lasnier E, Viallon M, Guéchot J, Hoeffel C, Arrivé L, Tubiana JM, Poupon R. Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C. Hepatology 2007; 46: 658-665.
15.
Taouli B, Tolia AJ, Losada M, Babb JS, Chan ES, Bannan MA, Tobias H. Diffusion-weighted MRI for quantification of liver fibrosis: preliminary experience. AJR Am J Roentgenol 2007; 189: 799-806.
16.
Sandrasegaran K, Akisik FM, Lin C, Tahir B, Rajan J, Saxena R, Aisen AM. Value of diffusion-weighted MRI for assessing liver fibrosis and cirrhosis. AJR Am J Roentgenol 2009; 193: 1556-1560.
17.
Goshima S, Kanematsu M, Watanabe H, Kondo H, Kawada H, Moriyama N, Bae KT. Gd-EOB-DTPA-enhanced MR imaging: prediction of hepatic fibrosis stages using liver contrast enhancement index and liver-to-spleen volumetric ratio. J Magn Reson Imaging 2012; 36: 1148-1153.
18.
Watanabe H, Kanematsu M, Goshima S, Kondo H, Onozuka M, Moriyama N, Bae KT. Staging hepatic fibrosis: comparison of gadoxetate disodium-enhanced and diffusion-weighted MR imaging: preliminary observations. Radiology 2011; 259: 142-150.
19.
Lee S, Choi D, Jeong WK. Hepatic enhancement of Gd-EOB-DTPA-enhanced 3 Tesla MR imaging: assessing severity of liver cirrhosis. J Magn Reson Imaging 2016; 44: 1339-1345.
20.
Li X, Liu H, Wang R, Yang J, Zhang Y, Li C. Gadoxetate-disodium-enhanced magnetic resonance imaging for liver fibrosis staging: a systematic review and meta-analysis. Clin Radiol 2020; 75: 319.e11-319.e19.
21.
Harada TL, Saito K, Araki Y, Matsubayashi J, Nagao T, Sugimoto K, Tokuuye K. Prediction of high-stage liver fibrosis using ADC value on diffusion-weighted imaging and quantitative enhancement ratio at the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI at 1.5 T. Acta Radiol 2018; 59: 509-516.
22.
Shimamoto D, Nishie A, Asayama Y, Ushijima Y, Takayama Y, Fujita N, Shirabe K, Hida T, Kubo Y, Honda H. MR prediction of liver function and pathology using Gd-EOB-DTPA: effect of liver volume consideration. Biomed Res Int 2015; 2015: 141853.
23.
Nojiri S, Kusakabe A, Fujiwara K, Shinkai N, Matsuura K, Iio E, Miyaki T, Joh T. Noninvasive evaluation of hepatic fibrosis in hepatitis C virus-infected patients using ethoxybenzyl-magnetic resonance imaging. J Gastroenterol Hepatol 2013; 28: 1032-1039.
24.
Jang HJ, Min JH, Lee JE, Shin KS, Kim KH, Choi SY. Assessment of liver fibrosis with gadoxetic acid-enhanced MRI: comparisons with transient elastography, ElastPQ, and serologic fibrosis markers. Abdom Radiol 2019; 44: 2769-2780.
25.
Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg 1964; 1: 1-85.
26.
Tsoris A, Marlar CA. Use of the child pugh score in liver disease. 2020 May 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan–. PMID: 31194448.
27.
Han D, Liu J, Jin E, He W. Liver assessment using Gd-EOB-DTPA-enhanced magnetic resonance imaging in primary biliary cholangitis patients. Jpn J Radiol 2019; 37: 412-419.
28.
Okada M, Ishii K, Numata K, Hyodo T, Kumano S, Kitano M, Kudo M, Murakami T. Can the biliary enhancement of Gd-EOB-DTPA predict the degree of liver function? Hepatobiliary Pancreat Dis Int 2012; 11: 307-313.
29.
Liang M, Zhao J, Xie B, Li C, Yin X, Cheng L, Wang J, Zhang L. MR liver imaging with Gd-EOB-DTPA: the need for different delay times of the hepatobiliary phase in patients with different liver function. Eur J Radiol 2016; 85: 546-552.
30.
Zizka J, Klzo L, Ferda J, Mrklovský M, Bukac J. Dynamic and delayed contrast enhancement in upper abdominal MRI studies: comparison of gadoxetic acid and gadobutrol. Eur J Radiol 2007; 62: 186-191.
31.
Ringe KI, Husarik DB, Sirlin CB, Merkle EM. Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver. AJR Am J Roentgenol 2010; 195: 13-28.
32.
Chen BB, Hsu CY, Yu CW, Wei SY, Kao JH, Lee HS, Shih TT. Clinical and histologic implications of delayed hepatobiliary enhancement on magnetic resonance imaging with gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid. Invest Radiol 2012; 47: 649-655.
33.
Kwee TC, Takahara T, Niwa T, Ivancevic MK, Herigault G, Van Cauteren M, Luijten PR. Influence of cardiac motion on diffusion-weighted magnetic resonance imaging of the liver. MAGMA 2009; 22: 319-325.
| eISSN: | 2300-6722 |
| ISSN: | 1899-1874 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
